15 Best Biotech Penny Stocks to Invest in Right Now

Page 7 of 13

7. Gossamer Bio, Inc. (NASDAQ:GOSS)

Year-to-Date Return: 237.02% 

Gossamer Bio, Inc. (NASDAQ:GOSS) is a late-stage clinical biopharmaceutical company focused on developing and commercializing seralutinib, an inhaled small molecule therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug targets multiple receptors, including PDGFR, colony-stimulating factor 1 receptor, and c-KIT, addressing high unmet medical needs in the PAH market. The company has secured licensing agreements for seralutinib and is positioning itself as a key player in this niche cardiovascular sector.

In September 2025, Gossamer Bio, Inc. (NASDAQ:GOSS)’s stock rose nearly 18% following FDA designations and positive developments in its seralutinib pipeline. The firm showcased its strategic focus on pulmonary hypertension treatments at multiple investor conferences, signaling strong growth ambitions. Management also approved inducement stock awards as part of employee incentive plans, underscoring confidence in long-term pipeline advancement, making it one of the best penny stocks to watch.

Financially, Gossamer Bio, Inc. (NASDAQ:GOSS) faces challenges with a net loss of approximately $38.3 million for the recent quarter and a negative shareholder equity position. However, gross margins remain near 100%, suggesting strong potential profitability upon commercialization. Analysts remain optimistic, with strong buy ratings. The ongoing Phase 3 PROSERA study is central to Gossamer Bio’s strategy. Seralutinib’s efficacy and safety results from this trial could support regulatory submissions and market approval, potentially opening access to an underserved PAH market.

Page 7 of 13